IPCA to sell Ankleshwar drug intermediates and active ingredients unit for Rs 22.15 crore

Core Business DivestedStrategic Transactions View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1287.50

prior close

₹1291.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.7%-1.8% vs market

Pharmaceuticals peers, median of 153sector+0.3%-1.4% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Midcap 150 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.1

15m

-1.0

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.7-1.8+0.3-1.4

Next day

-0.2+0.9-1.1+0.9-1.2

-0.7+0.7-1.5+0.6-1.4

-1.2+0.5-1.7+0.3-1.5

+0.7+1.3-0.6+0.3+0.4

+0.3+1.3-1.0+0.1+0.2

-0.2+1.7-1.9+0.7-0.9

15d

+3.3+2.8+0.5-1.0+4.3

+11.0+2.9+8.1-2.1+13.0

+11.2+2.5+8.7-4.2+15.4

+14.9-2.1+16.9-12.1+26.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IPCA Laboratories will sell its Ankleshwar unit making drug intermediates and active ingredients, along with related assets, to Suleshvari Pharma for Rs 22.15 crore in cash. The unit generated Rs 50.24 crore, or 0.74% of FY2025 income, against a written-down asset value of Rs 15.80 crore. The sale aims to cut operating costs. Completion is planned by December 31, 2025, subject to approvals and GIDC consent.

Likely market impact

The small unit is not expected to materially affect earnings. Cost savings may help margins, but completion needs approvals and GIDC consent.